<DOC>
	<DOC>NCT00928512</DOC>
	<brief_summary>This study will assess at Week 16 the efficacy and safety of AIN457 at different doses in patients with active RA despite stable MTX therapy. Treatment will continue up to Week 48 with a safety follow-up at Week 60 to assess the long term efficacy and safety of AIN457 treatment in combination with MTX in RA.</brief_summary>
	<brief_title>Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Presence of RA classified by ACR 1987 revised criteria. Patients with active RA should have been on MTX for at least 3 months and must currently be treated with a stable dose of MTX (&gt; or =7.5 mg/week &lt; or = 25 mg/week) for at least 4 weeks At Baseline: Disease activity criteria defined by &gt; or = 6 out of 28 tender joints and &gt; or = 6 out of 28 swollen joints WITH either Screening value of hsCRP &gt; or = 10 mg/L OR ESR &gt; or = 28 mm/1st hr RA patients functional status class IV classified according to the ACR 1991 revised criteria Patients taking high potency opioid analgesics (e.g., methadone, hydromorphone, or morphine) Any therapy by intraarticular injections (e.g. corticosteroid) required for treatment of acute RA flare within 4 weeks before randomization Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Rheumatoid Arthritis, RA, ACR, inflammatory joints</keyword>
</DOC>